TN2013000286A1 - Orally dispersible tablet - Google Patents

Orally dispersible tablet

Info

Publication number
TN2013000286A1
TN2013000286A1 TNP2013000286A TN2013000286A TN2013000286A1 TN 2013000286 A1 TN2013000286 A1 TN 2013000286A1 TN P2013000286 A TNP2013000286 A TN P2013000286A TN 2013000286 A TN2013000286 A TN 2013000286A TN 2013000286 A1 TN2013000286 A1 TN 2013000286A1
Authority
TN
Tunisia
Prior art keywords
granules
medicament
preparation
dispersible tablet
disintegrant
Prior art date
Application number
TNP2013000286A
Other languages
French (fr)
Inventor
Yutaka Tanoue
Tetsuya Matsuura
Yutaka Yamagata
Naoki Nagahara
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP2012/051279 external-priority patent/WO2012099260A1/en
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of TN2013000286A1 publication Critical patent/TN2013000286A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides a preparation with improved disintegration property, a preparation showing improved bioavailability of a medicament, production methods thereof and the like. A rapidly disintegrating preparation comprising granules comprising a medicament coated with a coating layer containing sugar or sugar alcohol; and a disintegrant. A production method of a rapidly disintegrating preparation including a step of producing granules comprising a medicament, a step of forming a coating layer containing sugar or sugar alcohol on the obtained granules and a step of mixing the coated granules with a disintegrant and molding the mixture.
TNP2013000286A 2011-10-14 2013-07-04 Orally dispersible tablet TN2013000286A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011227333 2011-10-14
PCT/JP2012/051279 WO2012099260A1 (en) 2011-01-17 2012-01-16 Orally dispersible tablet

Publications (1)

Publication Number Publication Date
TN2013000286A1 true TN2013000286A1 (en) 2015-01-20

Family

ID=46717925

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000286A TN2013000286A1 (en) 2011-10-14 2013-07-04 Orally dispersible tablet

Country Status (4)

Country Link
EP (1) EP2765985A1 (en)
JP (1) JP6061924B2 (en)
TN (1) TN2013000286A1 (en)
WO (1) WO2013054582A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3036201A1 (en) * 2016-09-15 2018-03-22 Skintech Life Science Limited Sublingual or buccal administration of dim for treatment of skin diseases
JP7407364B2 (en) * 2019-02-12 2024-01-04 日本ジェネリック株式会社 Ramelteon-containing solid preparation
CN110433142A (en) * 2019-09-06 2019-11-12 杭州百诚医药科技股份有限公司 A kind of ramelteon sublingual tablet and preparation method thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034239A (en) 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
PT914818E (en) 1996-06-14 2005-08-31 Kyowa Hakko Kogyo Kk TABLET OF FAST DISINTEGRATION BY INTRAORAL
JP3460538B2 (en) 1997-10-08 2003-10-27 救急薬品工業株式会社 Fast dissolving film preparation
US6663883B1 (en) 1999-08-26 2003-12-16 Takeda Chemical Industries, Ltd. Matrix adhering to nasal mucosa
JP4632499B2 (en) * 1999-08-26 2011-02-16 武田薬品工業株式会社 Nasal mucosa adhesion matrix
FR2834890B1 (en) 2002-01-23 2004-02-27 Servier Lab ORODISPERSIBLE PHARMACEUTICAL COMPOSITION OF AGOMELATIN
EP1867641A4 (en) * 2005-04-04 2010-01-13 Takeda Pharmaceutical Preventive or remedy for depression or anxiety neurosis
FR2894475B1 (en) * 2005-12-14 2008-05-16 Servier Lab ORODISPERSIBLE PHARMACEUTICAL COMPOSITION FOR OROMUCOSAL OR SUBLINGUAL ADMINISTRATION OF AGOMELATIN
KR20090029200A (en) * 2006-05-22 2009-03-20 반다 파마슈티칼즈, 인코퍼레이티드. Treatment for depressive disorders
US20080167363A1 (en) * 2006-12-28 2008-07-10 Braincells, Inc Modulation of Neurogenesis By Melatoninergic Agents
JP2008255064A (en) * 2007-04-06 2008-10-23 Takeda Chem Ind Ltd Sleep disorder-preventing and treating agent
JP2009136240A (en) 2007-12-10 2009-06-25 Lion Corp Chewing gum composition
JP5523913B2 (en) 2010-04-21 2014-06-18 スタンレー電気株式会社 Light source device and lighting device

Also Published As

Publication number Publication date
JP6061924B2 (en) 2017-01-18
WO2013054582A1 (en) 2013-04-18
EP2765985A1 (en) 2014-08-20
JP2014528395A (en) 2014-10-27

Similar Documents

Publication Publication Date Title
EA201391053A1 (en) TABLET DISPERSED IN THE MOUTH CAVITY
BR112013019223A2 (en) modified release dosage form, process for manufacturing a tablet and process for manufacturing an oral dosage form
WO2012131463A3 (en) Controlled release pharmaceutical dosage forms
CO6551722A2 (en) COMPOSITIONS AND PHARMACEUTICAL TABLETS WITH COATING OR COMPRESSIBLE AND MANUFACTURING METHODS
EP4248766A3 (en) Smokeless oral tobacco product and preparation thereof
EP2368544A4 (en) Orally rapidly disintegrating tablet, and process for producing same
EP2273975B8 (en) Pharmaceutical solutions, process of preparation and therapeutic uses
MX2013007057A (en) Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans.
WO2008046581A3 (en) Substituted tetrahydropyrrolopyrazine compounds and use thereof in medicaments
EP2246051A4 (en) Method for production of orally rapidly disintegrating tablet comprising imidafenacin as active ingredient
MX355086B (en) Sustained-release preparation of ivabradine or pharmaceutically acceptable salts thereof.
EP2204229A4 (en) Method of producing emulsion or dispersion and food, skin external preparation and drug containing emulsion or dispersion obtained by the production method
WO2010102778A3 (en) Substituted 3-aminoisoxazolopyridines as kcnq2/3 modulators
WO2011048563A3 (en) Orally disintegrating tablets of betahistine
CL2013001770A1 (en) Process for the manufacture of autoclaved fiber cement products; and autoclaved fiber cement product.
CA2863376A1 (en) Gastroretentive tablets
WO2014177585A3 (en) Biocatalytic production of nucleoside analogues as active pharmaceutical ingredients
AU2012319844A8 (en) Composite structure, packaging material and formed product using same, production methods thereof, and coating liquid
MX2014012799A (en) Tablets with coating and the production thereof.
WO2010012459A3 (en) A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
EP3345600A4 (en) Mirabegron-containing tablet, method for producing mirabegron-containing pharmaceutical preparation and method for producing mirabegron-containing granulated product
TN2013000286A1 (en) Orally dispersible tablet
IL213671A (en) Pharmaceutical compositions comprising aleglitazar, process for their manufacture and use thereof in the preparation of medicaments
MX359529B (en) Rapidly disintegrating coated tablets.
WO2010079045A3 (en) Crystalline salt forms of flibanserine